Aadi Bioscence announced that Baiteng Zhao joins Aadi‘s board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab in May. Prior to ProfoundBio, Zhao worked at Seagen, now part of Pfizer, for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AADI:
- Aadi Bioscience signs license agreement for ADC portfolio
- Aadi Bioscience selling Fyarro and infrastructure for $100M
- Aadi Bioscience Faces Potential Financial Strain from Securities Class Action Risks
- Aadi Bioscience Reports Q3 2024 Earnings and Growth
- Aadi Bioscience reports Q3 EPS (46c), consensus (46c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
